Scarica l'app Stockscreener
42.24
6.13%
-2.76
Dopo l'orario di chiusura:
41.15
-1.09
-2.58%
Precedente Chiudi:
$45.00
Aprire:
$44.25
Volume 24 ore:
688.66K
Relative Volume:
0.87
Capitalizzazione di mercato:
$2.06B
Reddito:
$140.49M
Utile/perdita netta:
$-153.49M
Rapporto P/E:
-15.33
EPS:
-2.7551
Flusso di cassa netto:
$-175.90M
1 W Prestazione:
-5.88%
1M Prestazione:
-8.79%
6M Prestazione:
+117.17%
1 anno Prestazione:
+121.04%
Intervallo 1D:
$41.85
$44.48
Intervallo di 1 settimana:
$41.85
$47.06
Portata 52W:
$15.86
$50.81
Urogen Pharma Ltd Stock (URGN) Company Profile
Nome
Urogen Pharma Ltd
Settore
Industria
Telefono
972 9 770 7601
Indirizzo
9 HA'TA'ASIYA ST, RA'ANANA
Compare URGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
42.24 | 2.20B | 140.49M | -153.49M | -175.90M | -2.7551 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Jefferies | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-06-16 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-19 | Ripresa | Ladenburg Thalmann | Buy |
| 2024-08-22 | Iniziato | Guggenheim | Buy |
| 2023-02-08 | Downgrade | Jefferies | Buy → Hold |
| 2022-04-27 | Iniziato | Berenberg | Buy |
| 2020-04-16 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-13 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-09 | Iniziato | National Securities | Neutral |
| 2019-05-30 | Iniziato | JP Morgan | Neutral |
| 2019-05-29 | Iniziato | Goldman | Neutral |
| 2019-01-29 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-04-04 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | Iniziato | Ladenburg Thalmann | Buy |
| 2017-11-15 | Reiterato | Oppenheimer | Outperform |
| 2017-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mostra tutto
Urogen Pharma Ltd Borsa (URGN) Ultime notizie
Jefferies reiterates UroGen Pharma stock rating on rival drug data By Investing.com - Investing.com Nigeria
UroGen Pharma's General Counsel Reports RSU Vesting and Tax-Related Share Sale - Kalkine Media
UroGen at Wells Fargo conference: launch gains and pipeline widen By Investing.com - Investing.com Canada
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares By Investing.com - Investing.com Canada
UroGen Pharma CMO Mark Schoenberg sells $37,383 in shares - Investing.com
Tyra Biosciences Shares Tumble 22% as Bladder Cancer Drug Misses Efficacy Benchmark - finance.biggo.com
UroGen Pharma (URGN) GC exercises RSUs, then sells shares for tax withholding - Stock Titan
UroGen Pharma advances with strong Zusduri sales and promising URGN-103 approval ahead - Pluang
Urogen Pharma: Upside After Bladder Cancer Launch (NASDAQ:URGN) - Seeking Alpha
UroGen Pharma (NASDAQ: URGN) officer plans 10,000-share sale after RSUs vest - Stock Titan
UroGen Pharma (URGN) officer lines up 5,000-share sale from RSUs - Stock Titan
Take the Zacks Approach to Beat the Markets: Oportun Financial, Uranium Royalty & Amgen in Focus - Zacks Investment Research
UroGen Pharma (NASDAQ:URGN) Combines High Growth Momentum with a Breakout Setup - ChartMill
UroGen Pharma Ltd (NASDAQ: URGN) Share Price, URGN Stock News, URGN Share Price & Updates - Kalkine
Nineteen new employees could receive up to 117,100 UroGen shares over three years. - Stock Titan
URGN Stock Price, Quote & Chart - ChartMill
UroGen Pharma Ltd. (URGN) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Trading the Move, Not the Narrative: (URGN) Edition - Stock Traders Daily
UroGen will speak at three investor events in September - Stock Titan
IntraGel Therapeutics Receives $7M Investment From UroGen Pharma - FinSMEs
UroGen Pharma Ltd. (URGN) Peer Comparison – Compare with Others - Value Research
UroGen Pharma Ltd. (URGN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Trade Alert: Chief Medical Officer Of UroGen Pharma Mark Schoenberg Has Sold Stock - Sahm
UroGen Pharma (URGN) Faces A Valuation Test Following Its FDA Filing - Sahm
UGN-103 NDA Filing for Recurrent Bladder Cancer Might Change The Case For Investing In UroGen Pharma (URGN) - Sahm
Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 27.14%: Read This Before Placing a Bet - Yahoo Finance
UroGen Pharma inks licensing deal with IntraGel Therapeutics - The Pharma Letter
UroGen Pharma Enters Option and Investment Deal with IntraGel Therapeutics - Kalkine Media
UroGen (NASDAQ: URGN) officer sold $750K in stock, plans more - Stock Titan
Cancer treatment co UroGen invests $7m in Israel’s IntraGelGlobes - Globes - Israel Business News
INTRAGEL THERAPEUTICS LTD announced that it expects to receive $7 million in funding from UroGen Pharma Ltd. - marketscreener.com
UroGen Pharma secures option deal with IntraGel for cancer tech By Investing.com - Investing.com Nigeria
IntraGel secures $7M from UroGen for cancer therapy development By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates UroGen Pharma stock rating on NDA filing By Investing.com - Investing.com Canada
UroGen Signs Investment, Collaboration Agreements With IntraGel for Access to Sustained-Release Platform - marketscreener.com
URGN Looks 90.6% Overvalued on GF Value™ - GuruFocus
UroGen inks equity and option deals with IntraGel (URGN:NASDAQ) - Seeking Alpha
UroGen Pharma secures option to license IntraGel SRGel program, agrees up to $7M investment - TradingView
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - The Manila Times
IntraGel's head and neck cancer drug study gets up to $7 million for Phase 2 - Stock Titan
UroGen gets an exclusive option on TumoCure after Phase 2 - Stock Titan
IntraGel secures $7M from UroGen for cancer therapy development - Investing.com
Urogen Pharma stock hits 52-week high at 49.69 USD By Investing.com - Investing.com South Africa
Urogen Pharma (NASDAQ:URGN) Reaches New 1-Year HighHere's What Happened - MarketBeat
Urogen Pharma stock hits 52-week high at 49.69 USD - Investing.com
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC - Sahm
Rice Hall James & Associates LLC Purchases Shares of 300,650 Urogen Pharma $URGN - MarketBeat
The Manufacturers Life Insurance Company Has $196,000 Stock Holdings in Urogen Pharma $URGN - MarketBeat
UroGen Pharma Submits US FDA New Drug Application for UGN-103 in Recurrent Bladder Cancer - marketscreener.com
UroGen submits FDA application for bladder cancer drug UGN-103 By Investing.com - Investing.com India
URGN Looks 84.5% Overvalued on GF Value™ - GuruFocus
Urogen Pharma Ltd Azioni (URGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):